TFS Announces Appointment of Dr. Birgitte Volck as Non-Executive Board Member

27 Jun, 2016, 08:00 ET from TFS International

LUND, Sweden, June 27, 2016 /PRNewswire/ --

TFS International is pleased to announce the appointment of Dr. Birgitte Volck as a non-executive Director to serve on the Company's Board of Directors.

Dr. Volck is the Senior Vice President, Head of R&D Rare Disease at GlaxoSmithKline in the UK. During the past 4 years she has been the Chief Medical Officer and Senior Vice President Development at Swedish Orphan Biovitrum (SOBI) leading the portfolio of products and product candidates in rare diseases across hemophilia, inflammation, neonatology and genetics, and metabolism. In addition, Dr. Volck has held senior R&D and medical affairs positions with Genzyme, Pharmexa and Amgen.

Dr. Volck received her medical degree and PhD from Copenhagen University (Denmark) and has published a number of abstracts and original papers in scientific journals on topics related to biochemical markers of inflammation and connective tissue metabolism in arthritis. She is an external lecturer at Copenhagen University and non-executive board member at Ascendis Pharma.

"I am excited to join the TFS Board of Directors. This is an opportunity to engage and contribute perspectives to the growth and strategic vision of TFS and the services the company offers based on my experience acquired through senior leadership roles in drug development, evidence generation and medical affairs," says Dr. Volck, new non-executive board member at TFS.

"We are pleased to welcome Dr. Birgitte Volck to our Board of Directors. She will add deep insight into R&D and in particular clinical development. She also has extensive experience working with small biotechs, midsize and large pharma. All areas of great importance to TFS and our customers," says Anders Ekblom, Board Chairman at TFS.

Information about TFS
TFS International is the leading, mid-size clinical Contract Research Organization (CRO) providing global clinical development solutions. Founded in 1996 in Sweden, TFS currently operates in over 25 countries throughout Europe and North America and employs more than 750 professionals. TFS core therapeutic areas of expertise are Oncology, Immunology, Dermatology, Ophthalmology, CNS, Cardiology and Endocrinology. Through two business areas, TFS Develop™ and  TFS People™, TFS provides services worldwide as end-to-end solutions or tactical functional services. Detailed information about TFS, and its business offerings can be obtained through http://www.tfscro.com​

For further information please contact:
Anders Ekblom
Board Chairman at TFS
Phone: +46(0)70-590-29-78


SOURCE TFS International